ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial
USA-based biotech major Amgen (Nasdaq: AMGN) and its subsidiary Onyx Pharmaceuticals announced the results of the Phase III ASPIRE trial, evaluating Kyprolis (carfilzomib) for injection plus Revlimid (lenalidomide) and dexamethasone compared with Revlimid and dexamethasone in relapsed multiple myeloma, at the 56th Annual Meeting of the American Society of Hematology (ASH).
The ASPIRE study met its primary endpoint and demonstrated that Kyprolis, Revlimid and dexamethasone significantly extended progression-free survival by 26.3 months, compared to 17.6 months in the Revlimid and dexamethasone arm.
Principal investigator Keith Stewart said: "The combination of carfilzomib, lenalidomide and low-dose dexamethasone generates deep and durable responses, provides a clinically meaningful improvement in progression-free survival and promises to be an important advancement in the treatment of myeloma."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze